68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

[1]  F. Montorsi,et al.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. , 2015, European urology.

[2]  W. Horninger,et al.  68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  U. Haberkorn,et al.  [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  S. Fanti,et al.  Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging 11C-Choline PET/CT Scan Before Salvage Radiation Therapy? , 2014, The Journal of Nuclear Medicine.

[6]  A. Buck,et al.  Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  U. Haberkorn,et al.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer , 2014, Pharmaceuticals.

[8]  S. Fanti,et al.  11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  M. Picchio,et al.  11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[12]  D. Rubello,et al.  11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT: A Sequential PET/CT Study , 2013, Clinical nuclear medicine.

[13]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  N. Lumen,et al.  Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. , 2013, Clinical genitourinary cancer.

[15]  R. Baum,et al.  Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity. , 2012, Bioconjugate chemistry.

[16]  A. Zietman,et al.  Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. , 2012, European urology.

[17]  Cordula Petersen,et al.  [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes , 2011, Radiation oncology.

[18]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[19]  F. Montorsi,et al.  PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  C. Nanni,et al.  Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy , 2009, Journal of Nuclear Medicine.

[21]  P. Carroll,et al.  A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. , 2008, The Journal of urology.

[22]  Richard K Valicenti,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Campana,et al.  Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney , 2006, Radiation Oncology (London, England).

[24]  P. Carroll.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy , 2004 .

[25]  C. Reddy,et al.  Recurrence‐free survival rates after external‐beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate‐specific antigen era , 2004, Cancer.

[26]  A. Partin,et al.  Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? , 2003, The Journal of urology.

[27]  M. Terris,et al.  Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. , 2003, Urology.

[28]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[29]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[30]  null Not Available.  World Medical Association Declaration of Helsinki , 2000 .

[31]  WMADo Helsinki.  World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. , 2000, Nursing ethics.

[32]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[34]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2014, European urology.

[35]  B. Hadaschik,et al.  I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014 .

[36]  V. Ambrosini,et al.  11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[38]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[39]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[40]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.